[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
News From the Centers for Disease Control and Prevention
January 9/16, 2008

Notice to Readers: Expansion of Use of Live Attenuated Influenza Vaccine (FluMist®) to Children Aged 2-4 Years and Other FluMist Changes for the 2007-08 Influenza Season

JAMA. 2008;299(2):166-167. doi:10.1001/jama.299.2.166

MMWR. 2007;56:1217-1219

On September 19, 2007, MedImmune Vaccines (Gaithersburg, Maryland) received approval from the Food and Drug Administration (FDA) to expand the use of FluMist®, a live, attenuated influenza vaccine (LAIV), to children aged 2-4 years (i.e., 24-49 months). FluMist is an intranasally administered influenza vaccine that was first licensed by the FDA in 2003 for healthy, nonpregnant persons aged 5-49 years.1 Expanding the age indications to include healthy children aged 2-4 years provides another influenza vaccination option for young children. In granting the new approval, FDA emphasized that FluMist is not approved for vaccination of children aged <2 years or adults aged >49 years, and that FluMist safety has not been established in persons with underlying medical conditions predisposing them to influenza-related complications.2 In addition, FluMist should not be administered to persons with asthma or children aged <5 years with recurrent wheezing.1,2